Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Latent human herpesvirus 6 is reactivated in CAR T cells.
Lareau CA, Yin Y, Maurer K, Sandor KD, Daniel B, Yagnik G, Peña J, Crawford JC, Spanjaart AM, Gutierrez JC, Haradhvala NJ, Riberdy JM, Abay T, Stickels RR, Verboon JM, Liu V, Buquicchio FA, Wang F, Southard J, Song R, Li W, Shrestha A, Parida L, Getz G, Maus MV, Li S, Moore A, Roberts ZJ, Ludwig LS, Talleur AC, Thomas PG, Dehghani H, Pertel T, Kundaje A, Gottschalk S, Roth TL, Kersten MJ, Wu CJ, Majzner RG, Satpathy AT. Lareau CA, et al. Among authors: kersten mj. Nature. 2023 Nov;623(7987):608-615. doi: 10.1038/s41586-023-06704-2. Epub 2023 Nov 8. Nature. 2023. PMID: 37938768 Free PMC article.
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
Kuipers MT, Spanjaart AM, Bonifazi F, diBlasi R, Zinzani PL, Thieblemont C, Baudet M, Biemond BJ, Kok WEM, Kersten MJ. Kuipers MT, et al. Among authors: kersten mj. Leuk Lymphoma. 2024 Mar;65(3):399-402. doi: 10.1080/10428194.2023.2288804. Epub 2023 Dec 9. Leuk Lymphoma. 2024. PMID: 38069804 No abstract available.
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Locke FL, et al. Among authors: kersten mj. Transplant Cell Ther. 2024 Nov;30(11):1065-1079. doi: 10.1016/j.jtct.2024.08.018. Epub 2024 Aug 24. Transplant Cell Ther. 2024. PMID: 39187161 Free article.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. Among authors: kersten mj. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk J, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Ghobadi A, et al. Among authors: kersten mj. Blood Adv. 2024 Jun 11;8(11):2982-2990. doi: 10.1182/bloodadvances.2023011532. Blood Adv. 2024. PMID: 38315832 Free PMC article. Clinical Trial.
Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles G, Rowe SP, Vardhanabhuti S, Winters J, Filosto S, To C, Cheng P, Schupp M, Korn R, Kersten MJ. Locke FL, et al. Among authors: kersten mj. Blood. 2024 Jun 13;143(24):2464-2473. doi: 10.1182/blood.2023021620. Blood. 2024. PMID: 38557775 Free PMC article. Clinical Trial.
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma.
Göbel C, Niccolai R, de Groot MHP, Jayachandran J, Traets J, Kloosterman DJ, Gregoricchio S, Morris B, Kreft M, Song JY, Azarang L, Kasa E, Oskam N, de Groot D, Hoekman L, Bleijerveld O, Kersten MJ, Aslam MA, Leeuwen FV, Jacobs H. Göbel C, et al. Among authors: kersten mj. Blood. 2025 Jan 10:blood.2024025500. doi: 10.1182/blood.2024025500. Online ahead of print. Blood. 2025. PMID: 39792929
Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands.
Meeuwes FO, Brink M, Plattel WJ, Vermaat JSP, Kersten MJ, Wondergem M, Visser O, van der Poel MWM, Oostvogels R, Woei-A-Jin FJSH, Böhmer L, Snijders TJF, Huls GA, Nijland M. Meeuwes FO, et al. Among authors: kersten mj. EJHaem. 2024 Nov 29;5(6):1215-1222. doi: 10.1002/jha2.1049. eCollection 2024 Dec. EJHaem. 2024. PMID: 39691269 Free PMC article.
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP. de Groot FA, et al. Among authors: kersten mj. Eur J Cancer. 2024 Dec;213:115068. doi: 10.1016/j.ejca.2024.115068. Epub 2024 Oct 13. Eur J Cancer. 2024. PMID: 39427440 Free article.
293 results